Center for Scientific Review; Notice of Closed Meetings, 23731-23732 [2021-09327]
Download as PDF
<![CDATA[
Federal Register / Vol. 86, No. 84 / Tuesday, May 4, 2021 / Notices
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Eleventh Meeting of the National
Clinical Care Commission
Office on Women’s Health,
Office of the Assistant Secretary for
Health, Office of the Secretary,
Department of Health and Human
Services.
ACTION: Notice.
AGENCY:
The National Clinical Care
Commission (the Commission) will
conduct its eleventh meeting virtually
on May 19 and June 1, 2021. The
Commission is charged to evaluate and
make recommendations to the U.S.
Department of Health and Human
Services (HHS) Secretary and Congress
regarding improvements to the
coordination and leveraging of federal
programs related to diabetes and its
complications.
DATES: The two-day meeting will take
place May 19 and June 1, 2021 from 1
p.m. to approximately 6 p.m. Eastern
Time (ET).
ADDRESSES: The meeting will be held
online via webinar. To register to attend
the meeting, please visit the registration
website at https://
kauffmaninc.adobeconnect.com/
ncccmeeting11/event/event_info.html.
FOR FURTHER INFORMATION CONTACT: Kara
Elam, Ph.D., MPH, MS, Designated
Federal Officer, National Clinical Care
Commission, U.S. Department of Health
and Human Services, Office on
Women’s Health, 200 Independence
Ave. SW, 7th Floor, Washington, DC
20201, Phone: (240) 435–9438, Email:
Kara.Elam@hhs.gov.
SUPPLEMENTARY INFORMATION: The
National Clinical Care Commission Act
(Pub. L. 115–80) requires the HHS
Secretary to establish the National
Clinical Care Commission. The
Commission consists of representatives
of specific federal agencies and nonfederal individuals who represent
diverse disciplines and views. The
Commission will evaluate and make
recommendations to the HHS Secretary
and Congress regarding improvements
to the coordination and leveraging of
federal programs related to diabetes and
its complications.
The eleventh meeting will be held
virtually, and each subcommittee will
present a summary of stakeholder calls
and all draft recommendations. This
will be followed by a discussion of the
recommendations. The final meeting
agenda will be available prior to the
meeting at https://health.gov/our-work/
health-care-quality/national-clinicalcare-commission/meetings.
khammond on DSKJM1Z7X2PROD with NOTICES
SUMMARY:
VerDate Sep<11>2014
17:13 May 03, 2021
Jkt 253001
23731
Authority: The National Clinical Care
Commission is required under the National
Clinical Care Commission Act (Pub. L. 115–
80). The Commission is governed by
provisions of the Federal Advisory
Committee Act (FACA), Public Law 92–463,
as amended (5 U.S.C., App.) which sets forth
standards for the formation and use of federal
advisory committees.
Name of Committee: National Institute of
Mental Health Special Emphasis Panel; Early
Phase Psychosocial and Confirmatory
Efficacy Clinical Trials.
Date: June 2, 2021.
Time: 11:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Neuroscience Center, 6001 Executive
Boulevard, Rockville, MD 20852 (Telephone
Conference Call).
Contact Person: Marcy Ellen Burstein,
Ph.D., Scientific Review Officer, Division of
Extramural Activities, National Institute of
Mental Health, NIH, Neuroscience Center,
6001 Executive Blvd., Room 6143, MSC 9606,
Bethesda, MD 20892–9606, 301–443–9699,
bursteinme@mail.nih.gov.
Name of Committee: National Institute of
Mental Health Special Emphasis Panel;
Effectiveness Studies.
Date: June 3, 2021.
Time: 11:30 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Neuroscience Center, 6001 Executive
Boulevard, Rockville, MD 20852 (Telephone
Conference Call).
Contact Person: Nicholas Gaiano, Ph.D.,
Review Branch, Chief Division of Extramural
Activities, National Institute of Mental
Health, NIH, Neuroscience Center/Room
6150/MSC 9606, 6001 Executive Boulevard,
Bethesda, MD 20892–9606, 301–443–2742,
nick.gaiano@nih.gov.
(Catalogue of Federal Domestic Assistance
Program No. 93.242, Mental Health Research
Grants, National Institutes of Health, HHS)
Dated: April 27, 2021.
Dorothy A. Fink,
Deputy Assistant Secretary for Women’s
Health.
Dated: April 29, 2021.
Melanie J. Pantoja,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2021–09277 Filed 5–3–21; 8:45 am]
[FR Doc. 2021–09375 Filed 5–3–21; 8:45 am]
BILLING CODE 4150–32–P
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institutes of Health
National Institute of Mental Health;
Notice of Closed Meetings
Center for Scientific Review; Notice of
Closed Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Public Participation at Meeting: The
Commission invites public comment on
issues related to the Commission’s
charge. There will be an opportunity for
limited oral comments (each no more
than 3 minutes in length) at this virtual
meeting. Virtual attendees who plan to
provide oral comments at the
Commission meeting during a
designated time must register prior to
the meeting at https://
kauffmaninc.adobeconnect.com/
ncccmeeting11/event/event_info.html.
Written comments are welcome
throughout the entire development
process of the Commission’s work and
may be emailed to OHQ@hhs.gov.
Written comments should not exceed
three pages in length.
Individuals who need special
assistance, such as sign language
interpretation or other reasonable
accommodations, should indicate the
special accommodation when
registering online or by notifying
Jennifer Gillissen at jennifer.gillissen@
kauffmaninc.com by May 10, 2021.
PO 00000
Frm 00062
Fmt 4703
Sfmt 4703
E:\FR\FM\04MYN1.SGM
04MYN1
khammond on DSKJM1Z7X2PROD with NOTICES
23732
Federal Register / Vol. 86, No. 84 / Tuesday, May 4, 2021 / Notices
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Fellowship:
Infectious Disease and Immunology B.
Date: May 20, 2021.
Time: 10:00 a.m. to 11:30 a.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Uma Basavanna, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, 6701 Rockledge Drive,
Bethesda, MD 20892, 301–435–1199,
uma.basavanna@nih.gov.
This notice is being published less than 15
days prior to the meeting due to the timing
limitations imposed by the review and
funding cycle.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; RFA RM20–
022: Faculty Institutional Recruitment for
Sustainable Transformation (FIRST) Program.
Date: June 4, 2021.
Time: 9:30 a.m. to 7:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Elia K. Ortenberg, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 3108,
MSC 7816, Bethesda, MD 20892, (301) 827–
7189, femiaee@csr.nih.gov.
Name of Committee: Cardiovascular and
Respiratory Sciences Integrated Review
Group; Cardiovascular Differentiation and
Development Study Section.
Date: June 7, 2021.
Time: 9:30 a.m. to 7:30 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Sara Ahlgren, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 4136,
Bethesda, MD 20817–7814, 301–435–0904,
sara.ahlgren@nih.gov.
Name of Committee: Biological Chemistry
and Macromolecular Biophysics Integrated
Review Group; Synthetic and Biological
Chemistry A Study Section.
Date: June 8–9, 2021.
Time: 10:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Anita Szajek, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 4187,
Bethesda, MD 20892, 301–827–6276,
anita.szajek@nih.gov.
Name of Committee: Oncology 1-Basic
Translational Integrated Review Group;
Cancer Genetics Study Section.
Date: June 10–11, 2021.
Time: 9:00 a.m. to 5:00 p.m.
VerDate Sep<11>2014
17:13 May 03, 2021
Jkt 253001
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Juraj Bies, Ph.D., Scientific
Review Officer, Center for Scientific Review,
National Institutes of Health, 6701 Rockledge
Drive, Room 4158, MSC 7806, Bethesda, MD
20892, 301–435–1256, biesj@mail.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.306, Comparative Medicine;
93.333, Clinical Research, 93.306, 93.333,
93.337, 93.393–93.396, 93.837–93.844,
93.846–93.878, 93.892, 93.893, National
Institutes of Health, HHS)
Dated: April 29, 2021.
Ronald J. Livingston, Jr.,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2021–09327 Filed 5–3–21; 8:45 am]
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute on Aging; Notice of
Closed Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute on
Aging Special Emphasis Panel; SenescenceCell Death Decisions in Aging.
Date: June 4, 2021.
Time: 12:30 p.m. to 5:30 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institute on Aging,
Gateway Building, 7201 Wisconsin Avenue,
Bethesda, MD 20892 (Video Meeting).
Contact Person: Joshua Jin-Hyouk Park,
Ph.D., Scientific Review Officer, Scientific
Review Branch, National Institute on Aging,
National Institutes of Health, Gateway
Building 2W200, 7201 Wisconsin Avenue,
Bethesda, MD 20892, (301) 496–6208,
joshua.park4@nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.866, Aging Research,
National Institutes of Health, HHS)
Frm 00063
Fmt 4703
[FR Doc. 2021–09328 Filed 5–3–21; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Prospective Grant of an Exclusive
Patent License: Development and
Commercialization of Cell Therapies
for Cancer
AGENCY:
National Institutes of Health,
HHS.
ACTION:
Notice.
The National Cancer Institute,
an institute of the National Institutes of
Health, Department of Health and
Human Services, is contemplating the
grant of an Exclusive Patent License to
practice the inventions embodied in the
Patents and Patent Applications listed
in the Supplementary Information
section of this Notice to Ziopharm
Oncology, Inc. (‘‘Ziopharm’’),
headquartered in Boston, MA.
DATES: Only written comments and/or
applications for a license which are
received by the National Cancer
Institute’s Technology Transfer Center
on or before May 19, 2021 will be
considered.
ADDRESSES: Requests for copies of the
patent applications, inquiries, and
comments relating to the contemplated
Exclusive Patent License should be
directed to: Andrew Burke, Ph.D.,
Senior Technology Transfer Manager,
NCI Technology Transfer Center,
Telephone: (240) 276–5484; Email:
andy.burke@nih.gov.
SUPPLEMENTARY INFORMATION:
SUMMARY:
BILLING CODE 4140–01–P
PO 00000
Dated: April 28, 2021.
Miguelina Perez,
Program Analyst, Office of Federal Advisory
Committee Policy.
Sfmt 4703
Intellectual Property
Group A
E–190–2020: HLA Class I-Restricted T
Cell Receptors Against RAS With G12V
Mutation
1. United States Provisional Patent
Application No. 63/060,340, filed
August 3, 2020 (NCI Reference E–190–
2020–0–US–01) and U.S., PCT and
foreign patent applications claiming
priority to the aforementioned
application.
The patent rights in these inventions
have been assigned and/or exclusively
licensed to the government of the
United States of America.
The prospective exclusive license
territory may be worldwide, and the
E:\FR\FM\04MYN1.SGM
04MYN1
]]>Agencies
[Federal Register Volume 86, Number 84 (Tuesday, May 4, 2021)]
[Notices]
[Pages 23731-23732]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2021-09327]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Center for Scientific Review; Notice of Closed Meetings
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended, notice is hereby given of the following meetings.
The meetings will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C., as amended. The grant applications and the discussions could
disclose confidential trade secrets or commercial property such as
patentable material, and personal information concerning individuals
associated with the grant applications, the disclosure of which would
constitute a clearly unwarranted invasion of personal privacy.
[[Page 23732]]
Name of Committee: Center for Scientific Review Special Emphasis
Panel; Fellowship: Infectious Disease and Immunology B.
Date: May 20, 2021.
Time: 10:00 a.m. to 11:30 a.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, Rockledge II, 6701
Rockledge Drive, Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Uma Basavanna, Ph.D., Scientific Review Officer,
Center for Scientific Review, 6701 Rockledge Drive, Bethesda, MD
20892, 301-435-1199, [email protected].
This notice is being published less than 15 days prior to the
meeting due to the timing limitations imposed by the review and
funding cycle.
Name of Committee: Center for Scientific Review Special Emphasis
Panel; RFA RM20-022: Faculty Institutional Recruitment for
Sustainable Transformation (FIRST) Program.
Date: June 4, 2021.
Time: 9:30 a.m. to 7:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, Rockledge II, 6701
Rockledge Drive, Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Elia K. Ortenberg, Ph.D., Scientific Review
Officer, Center for Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 3108, MSC 7816, Bethesda, MD
20892, (301) 827-7189, [email protected].
Name of Committee: Cardiovascular and Respiratory Sciences
Integrated Review Group; Cardiovascular Differentiation and
Development Study Section.
Date: June 7, 2021.
Time: 9:30 a.m. to 7:30 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, Rockledge II, 6701
Rockledge Drive, Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Sara Ahlgren, Ph.D., Scientific Review Officer,
Center for Scientific Review, National Institutes of Health, 6701
Rockledge Drive, Room 4136, Bethesda, MD 20817-7814, 301-435-0904,
[email protected].
Name of Committee: Biological Chemistry and Macromolecular
Biophysics Integrated Review Group; Synthetic and Biological
Chemistry A Study Section.
Date: June 8-9, 2021.
Time: 10:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, Rockledge II, 6701
Rockledge Drive, Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Anita Szajek, Ph.D., Scientific Review Officer,
Center for Scientific Review, National Institutes of Health, 6701
Rockledge Drive, Room 4187, Bethesda, MD 20892, 301-827-6276,
[email protected].
Name of Committee: Oncology 1-Basic Translational Integrated
Review Group; Cancer Genetics Study Section.
Date: June 10-11, 2021.
Time: 9:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, Rockledge II, 6701
Rockledge Drive, Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Juraj Bies, Ph.D., Scientific Review Officer,
Center for Scientific Review, National Institutes of Health, 6701
Rockledge Drive, Room 4158, MSC 7806, Bethesda, MD 20892, 301-435-
1256, [email protected].
(Catalogue of Federal Domestic Assistance Program Nos. 93.306,
Comparative Medicine; 93.333, Clinical Research, 93.306, 93.333,
93.337, 93.393-93.396, 93.837-93.844, 93.846-93.878, 93.892, 93.893,
National Institutes of Health, HHS)
Dated: April 29, 2021.
Ronald J. Livingston, Jr.,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2021-09327 Filed 5-3-21; 8:45 am]
BILLING CODE 4140-01-P
